(1) Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; (2) proposed appointment of director and determination of the director's remuneration; and (3) notice of the 2026 first extraordinary general meeting
Filed with HKEX · Stock code 2509 ·
6ix is reading this filing.
View original source (HKEXnews)Qyuns Therapeutics Co., Ltd. on 6ix
Earlier from Qyuns Therapeutics
- Announcement book closure period for extraordinary general meeting
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement phase III clinical study results of Oturkibart (QX005N) for treatment of prurigo nodularis presented as a late-breaking oral presentation at EADV 2026
- List of directors and their roles and functions
- Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; and resignation and proposed appointment of non-executive director
Later from Qyuns Therapeutics
- Notice of the 2026 first extraordinary general meeting
- Form of proxy for the extraordinary general meeting to be held on Friday, November 13, 2026
- Documents on Display
Follow Qyuns Therapeutics into a list and get an email when it puts out news.
Follow Qyuns Therapeutics